When Clinical Trials Blow up — a Sell Recommendation
This morning, this company announced that its lead program, CO-101 for advanced metastatic pancreatic cancer has failed in a Phase 2 trial. Furthermore, they announced it is terminating the program.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.